All right, let's get to it. A mad dash before we get you to the opening bell a little more than two minutes from now. Talk a little Lily.Of course, they did a deal a couple of days ago as well in the biotech area. >> You know, one of the things that you you kind your eyes glaze over these deals that are under 10 billion. They bought Centessa for 7.8% billion.I just said, "Oh, it's a sleep disorder thing." No, it's a peptide uh that impacts brain for many, many different ways, not just for sleep. And a lot o ...

Core Insights - BullFrog AI has entered a commercial agreement with a top 5 global pharmaceutical company to utilize its bfLEAP platform for drug discovery in major depressive disorder (MDD) [1][2] - The MDD market was valued at over $8 billion in 2025 and is projected to grow at nearly 5% annually, exceeding $11 billion by 2032 [1] - The agreement provides exclusive access to a target candidate, indicating a significant validation of BullFrog AI's capabilities [1][2] Company Overview - BullFrog AI specializes in using artificial intelligence and machine learning to analyze complex biomedical data, aiming to enhance drug discovery and development [4] - The company's bfLEAP platform integrates causal network inference to assist drug developers in identifying and prioritizing drug targets for complex diseases like MDD [2][4] - BullFrog AI collaborates with leading research institutions to streamline therapeutic development and reduce clinical trial failure rates [4] Industry Context - Major depressive disorder (MDD) is a leading cause of disability worldwide and is projected to become the top burden of disease by 2030 [3] - The increasing prevalence of MDD highlights the growing need for effective drug discovery solutions, positioning BullFrog AI's technology as a valuable asset in the pharmaceutical industry [3]

Multiomics is about capturing the multiple biological layers, DNA, RNA, and more that together shape health and disease. We view AI as a lynchpin reinforcing a powerful flywheel of innovation across multiomics as biological data scales, models improve, and in turn enabling better therapeutics, tools, and diagnostics. In effect, a virtuous cycle.The cost collapse for biological data is striking. The first human reference genome took more than a decade and nearly $3 billion to produce. That was about 25 years ...

For labs at universities, biotech firms and big pharma companies alike, AI models are offering new possibilities for drug discovery.Using those models, though, is rarely as simple as using a chatbot. They are generally fitted to different tasks, whether that’s predicting protein structures, optimizing chemical reactions or any of the other myriad tasks involved in researching new medicine. What’s more, they typically require additional training and a level of machine learning sophistication that many biolog ...

Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statem ...

Core Viewpoint - Cosmos Health Inc. has appointed Dr. Dimitrios Iliopoulos to its Advisory Board to enhance its biotechnology initiatives, particularly in AI-driven drug discovery and clinical-stage therapeutic development [1][7]. Group 1: Appointment and Expertise - Dr. Iliopoulos is a recognized expert in artificial intelligence, drug discovery, and drug development, currently serving as Co-Founder and CEO of Athos Therapeutics Inc., which focuses on precision therapeutics for autoimmune diseases [2]. - He has a strong academic background, having served as an Assistant Professor at Harvard Medical School and a tenured Associate Professor at UCLA, where he founded the UCLA Center for Systems Biomedicine [3]. - Dr. Iliopoulos has received numerous awards for his contributions to drug development and has published over 130 peer-reviewed articles, with more than 24,000 citations [4]. Group 2: Contributions to Drug Discovery - He has developed innovative AI-enabled strategies that have accelerated drug discovery in oncology and autoimmune diseases, including the identification of metformin's anti-cancer properties [5]. - His research at UCLA led to the identification of miR-124 as a key target for ulcerative colitis, contributing to clinical development programs in inflammatory bowel disease [5]. Group 3: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [8]. - The company manufactures pharmaceuticals and other health products through its subsidiary, Cana Laboratories S.A., which is certified by the European Medicines Agency [8]. - Cosmos Health is expanding its R&D initiatives targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [9].

Core Insights - Recursion, a clinical stage TechBio company, will be featured in a Lightning Talk at the NVIDIA GTC AI Conference, focusing on the integration of AI, automation, and robotics in drug discovery and development [1][4] Company Overview - Recursion is a leading TechBio company that decodes biology to improve lives, utilizing a platform called Recursion OS to generate one of the largest proprietary biological and chemical datasets [5] - The company operates sophisticated integrated wet and dry labs for AI drug discovery, generating millions of multi-omic data points weekly to enhance the drug discovery process [3][5] - Recursion's operations are supported by its powerful supercomputer, BioHive-2, which facilitates end-to-end improvements in drug discovery, including biological discoveries, precision drug design, and optimized clinical trials [3][5] Collaboration and Technology - Recursion is collaborating with HighRes Biosolutions to develop self-driving, high-throughput labs using advanced automation and orchestration technologies [2] - The collaboration leverages HighRes technologies such as robotic perception and digital twins of laboratory environments, which are essential for creating self-driving laboratories [2] Industry Impact - The advancements in AI and accelerated computing are pushing the boundaries of drug discovery, with NVIDIA's involvement highlighting the transition from concept to reality in Physical AI [4]

Core Insights - Advanced Biomed Inc. has entered into a clinical research collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study on its A+PerfusC platform, aimed at evaluating predictive accuracy in oncology treatment selection [1][2]. Group 1: Study Details - The feasibility study is a non-interventional clinical research project approved by the Institutional Review Board, with case collection starting in early February 2026 and full completion targeted by year-end 2026 [2]. - Interim comparative data from the study is expected in May–June 2026, focusing on the correlation between drug sensitivity results from the A+PerfusC platform and actual patient clinical outcomes [2][4]. Group 2: Technological Advantages - The A+PerfusC platform utilizes label-free microfluidic technology to isolate high-viability circulating tumor cells, enabling automated 3D culture arrays for parallel drug testing, which addresses limitations of traditional 2D models and xenograft animal models [3][4]. - This innovative approach aims to reduce the time to evidence-based treatment decisions and minimize patient exposure to ineffective therapies [3]. Group 3: Collaboration and Future Plans - The collaboration with Chi-Mei Medical Center will involve joint clinical research and commercial development, with both parties sharing rights to project-related intellectual property and research outcomes [5]. - The results from the feasibility study are expected to inform the design of larger clinical validation studies and support the A+PerfusC platform's use as a predictive tool for treatment response [4]. Group 4: Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through a subsidiary in Taiwan [6][7]. - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with plans for regulatory clearances in Taiwan and future global expansion [7].

Earlier this week, we revealed the exciting progress we’ve been making at @IsomorphicLabs. Here, our President, @maxjaderberg, explains the significance of our breakthroughs and how they are reshaping the future of drug discovery.Check out his thread for more 🧵Max Jaderberg (@maxjaderberg):The Iso team has cooked something incredible: our new technical report unveils the latest results from our drug design engine, the IsoDDE, progressing far beyond AlphaFold 3. This breaks new ground compared to AF and othe ...

FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on February 10, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 401 ...